Anastrozole SWISSPHARMA 1mg/30 Tablets: Product Overview

Understanding the Composition, Medical Applications, and Safety Profile

Product Introduction

Anastrozole SWISSPHARMA 1mg/30 Tablets Online Poland is a product identified by the active ingredient anastrozole, with a stated strength of 1 mg per tablet and a pack size of 30 tablets. Anastrozole belongs to a class of medicines known as aromatase inhibitors. These medicines influence the body's production of oestrogen, a hormone that plays an important role in several physiological processes.

The product name provides basic information about its stated ingredient, strength, and quantity. However, the manufacturer's complete formulation details, tablet appearance, excipients, and regulatory status should be confirmed through the original packaging and accompanying product documentation. The information below explains the established medical context of anastrozole without assuming that every detail has been independently verified for this particular SWISSPHARMA presentation.

Product Composition and Presentation

The product is described as containing anastrozole at a strength of 1 mg per tablet. The stated pack contains 30 tablets, making it important to distinguish the strength of each individual tablet from the total number supplied.

• Product name: Anastrozole SWISSPHARMA
• Active ingredient stated: Anastrozole
• Strength stated: 1 mg per tablet
• Pack size stated: 30 tablets
• Medicine category: Aromatase inhibitor
• Route associated with standard anastrozole tablets: Oral administration
• Product verification: Confirm the manufacturer's label, batch details, expiry date, and official product information.

The 1 mg strength is used in established prescription anastrozole medicines. Nevertheless, the exact appearance, inactive ingredients, storage instructions, and approved indications for a particular branded pack should be taken from its verified documentation rather than inferred from the product name alone.

What Is Anastrozole?

Anastrozole is a non-steroidal aromatase inhibitor. Aromatase is an enzyme responsible for converting certain androgens into oestrogens. By inhibiting this enzyme, anastrozole reduces the amount of oestrogen produced through this pathway.

In women after menopause, the ovaries produce substantially less oestrogen than they did before menopause. Other tissues, including fatty tissue, continue to contribute to oestrogen production through aromatase activity. Reducing this production can be clinically useful in selected hormone-sensitive breast cancers.

Anastrozole works differently from medicines that directly block oestrogen receptors. Its primary action is to reduce oestrogen synthesis rather than simply prevent the hormone from attaching to its receptor. This distinction explains why its use is closely linked to hormone status, diagnosis, and the treatment plan established by a qualified clinician.

Medical Applications of Anastrozole

The established medical role of anastrozole is primarily associated with hormone receptor-positive breast cancer in postmenopausal women. In this setting, oestrogen can stimulate the growth of certain cancer cells. Lowering oestrogen production may help reduce this hormonal stimulation.

Depending on the applicable prescribing information and individual clinical circumstances, anastrozole may be prescribed for:

Adjuvant treatment of early breast cancer: Followin